A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2, Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 671
- Population
- ALL · 50 Years to 89 Years
- Duration
- 2020-12-29 to 2027-11-01
- Intervention
- ABBV-RGX-314; Ranibizumab (LUCENTIS®)
- Comparator
- Control Arm
- Outcomes measured
- Mean change from baseline in Best Corrected Visual Acuity (BCVA) — At Week 54; Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEs — Week 50; Incidences of ocular and overall AEs over 54 weeks — Through Week 54; Incidences of ocular and overall AEs over 98 weeks — Through Week 98; Mean change from baseline in BCVA to Week 98 (ABBV-RGX-314 randomized participants) based on the ETDRS score — Week 98; Proportion of participants with worsened BCVA — Week 54; Week 98; Proportion of participants with improved BCVA — Week 54; Week 98; Proportion of participants (1) gaining > 0 letters; (2) losing > 0 letters; maintaining vision (not losing ≥ 15 letters…; Mean change from baseline in BCVA for participants who received 0 or more supplemental anti-VEGF injections (ABBV-RGX-3…; Mean change from Week 54 to Week 98 in BCVA (control arm participants who cross over to ABBV-RGX-314) — Week 54 to Week…; Mean change from baseline in CRT as measured by SD-OCT — Week 54; (ABBV-RGX-314 randomized participants) Week 98; Mean change from Week 54 to Week 98 in CRT as measured by SD-OCT (control arm participants who cross over to ABBV-RGX-3…; Mean change from baseline in CPT as measured by SD-OCT — Week 54; (ABBV-RGX-314 randomized participants) Week 98; Mean change from Week 54 to Week 98 in CPT as measured by SD-OCT (control arm participants who cross over to ABBV-RGX-3…; Mean number of supplemental anti-VEGF injections from Baseline through Week 54 (ABBV-RGX-314 randomized participants) a…; Proportion of participants with 0, 1, 2, and 3 supplemental injections through Week 54 and Week 98 (ABBV-RGX-314 random…; Proportion of participants with ≤ 1, ≤ 2, and ≤ 3 supplemental injections through Week 54 and Week 98 (ABBV-RGX-314 ran…; Proportion of participants that received 1 or 2 injections through Week 54 and Week 98 (ABBV-RGX-314 randomized partici…; Proportion of participants with a reduction of ≥ 50% in anti-VEGF injection annualized rate through Week 54 and Week 98…; Proportion of participants with a reduction of ≥ 75% in anti-VEGF injection annualized rate through Week 54 and Week 98…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.